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Abstract
Introduction A protein analysis using a mass spectrometry
indicated that there are serum proteins showing significant
quantitative changes after the administration of infliximab.
Among them, connective tissue growth factor (CTGF) seems to
be related to the pathogenesis of rheumatoid arthritis (RA).
Therefore, this study was conducted to investigate how CTGF
is associated with the disease progression of RA.
Methods Serum samples were collected from RA patients in
active or inactive disease stages, and before or after treatments
with infliximab. CTGF production was evaluated by ELISA, RT-
PCR, indirect immunofluorescence microscopy, and
immunoblotting. Osteoclastogenesis was evaluated using
tartrate-resistant acid phosphatase (TRAP) staining, a bone
resorption assay and osteoclasts specific catalytic enzymes
productions.
Results The serum concentrations of CTGF in RA were greater
than in normal healthy controls and disease controls.
Interestingly, those were significantly higher in active RA
patients compared to inactive RA patients. Furthermore, the
CTGF levels significantly were decreased by infliximab
concomitant with the disease amelioration. In addition, tumour
necrosis factor (TNF)α can induce the CTGF production from
synovial fibroblasts even though TNFα can oppositely inhibit the
production of CTGF from chondrocytes. CTGF promoted the
induction of the quantitative and qualitative activities of
osteoclasts in combination with M-CSF and receptor activator
of NF-κB ligand (RANKL). In addition, we newly found integrin
αVβ3 on the osteoclasts as a CTGF receptor.
Conclusions These results indicate that aberrant CTGF
production induced by TNFα plays a central role for the
abnormal osteoclastic activation in RA patients. Restoration of
aberrant CTGF production may contribute to the inhibition of
articular destruction in infliximab treatment.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder
that ultimately leads to the destruction of the joint architecture.
Although the precise pathogenic mechanisms leading to the
development of RA are not fully understood, proinflammatory
cytokines, such as tumor necrosis factor-α (TNF-α), interleukin
CRP: C reactive protein; CTGF: connective tissue growth factor; ERK: extracellular signal-regulated kinase; ESR: erythrocyte sedimentation rate; 
FAK: focal adhesion kinase; M-CSF: Macrophage colony-stimulating factor; MMP: matrix metalloproteinase; NF-κB: nuclear factor-kappa B; OA: oste-
oarthropathy; RA: rheumatoid arthritis; SLE: systemic lupus erhythematosus; SS: Sjögren's Syndrome; TRAP: tartrate-resistant acid phosphatase; 
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(IL)-1 and IL-6 play pivotal roles in the induction of RA [1-4].
Especially, TNF-α is considered to play a central role in bone
destruction because TNF-α mediates an abnormal activation
of osteoclasts through either the direct or indirect mechanisms
in RA [2,3]. The use of TNF-α blockade reagents has been
shown to have a significant impact on the therapy of RA and
the success of this therapy has led to trials in other chronic
inflammatory diseases such as Behcet's disease [5-8]. Inflixi-
mab is chimeric IgG1 anti-TNF-α antibody containing the anti-
gen-binding region of a mouse antibody and the constant
region of human antibody [9]. The antibody binds soluble and
membrane bound TNF-α, thereby impairing binding to its
receptor. Although anti-TNF-α blocking reagents possess a
beneficial effect for RA therapy especially for prevention of
articular destruction, the precise mechanism of the disease's
amelioration has not been clarified because TNF-α has multi-
ple functions and it is involved in many inflammatory pathways
and it also regulates various physiological phenomena in RA
patients [7,8].
A previous study has shown the changes in the profiles of
serum protein biomarkers in infliximab-treated RA patients. It
was achieved by a novel approach to proteomic research
using a specially developed serum/plasma protein separation
device (hollow-fiber-membrane-based device; HFRD, Toray
Industry, Tokyo, Japan) and a linked two-dimensional liquid
chromatography system (2D LC-MS/MS) [10]. Various pro-
teins (approximately 20 kinds of proteins) revealed great
changes in their expression after the infliximab treatment using
this analytical system, however, many proteins among them
were cellular constitutive proteins. These were thought to be
released into sera from cells destroyed by anti-TNF-α antibod-
ies because the antibodies are known to mediate the killing of
cells expressing TNF-α on the surface [9]. Among these pro-
teins listed in the previous study [10], connective tissue
growth factor (CTGF) appeared to be a potent strong biomar-
ker in the infliximab-treated RA patients. CTGF was discov-
ered due to the cross-reactivity of a platelet derived growth
factor (PDGF) antiserum with a single polypeptide with a
molecular weight of 38 kDa secreted by cultured human vein
endothelial cells (HUVEC), and its cDNA was isolated from a
HUVEC cDNA expression library with anti-PDGF and shown
to encode a 349-amino acid protein [11]. CTGF is a member
of the CCN protein family (including Cyr61 (CCN1), CTGF
(CCN2) and Nov) and believed to be a downstream mediator
of transforming growth factor (TGF)-α action [12]. Although a
number of cell surface molecules have been nominated as
candidates currently for its specific receptors, they have not
been defined to date. CTGF is a bioactive cytokine, therefore,
it is considered not to be derived from these destroyed cells.
Furthermore, it has been shown that CTGF is associated with
several biological functions such as fibrosis, tumorgenesis,
angiogenesis, and endochondral ossification, and it has been
proposed that CTGF produced by chondrocytes might main-
tain a homeostasis of cartilage tissue by autocrine system
[13,14]. Articular tissue consists of not only chondrocytes but
also various kinds of cells such as synovial fibroblasts or oste-
oclasts. Especially, fibroblasts of inflamed synovial tissue and
osteoclasts are thought to be the main effecter cells for the
development of bone destruction in RA. However, precise
functions of CTGF on these articular cells have not been elu-
cidated so far.
Based on these findings, the contribution of CTGF for RA
pathogenesis was investigated in the current study. Here, we
report that aberrant CTGF production mediated by TNF-α can
induce massive osteoclastogenesis and disturbance on home-
ostasis of cartilage resulting in bone and cartilage tissue dam-
age in RA. Furthermore, we report here that phosphorylated
extracellular signal-regulated kinase (ERK) 1/2 was recruited
by CTGF stimulation on activation of the signal transduction
pathway associated with integrin αVβ3 and contributed to
focal adhesion kinase (FAK) activation on the osteoclasts.
These data indicate that we found integrin αVβ3 as a CTGF
receptor on the osteoclasts. We insist that CTGF is a poten-
tially novel effecter molecule for RA pathogenesis and our data
could help better understanding for elucidation of the protec-
tive mechanisms for bone destruction associated with the effi-
cacy of infliximab treatment. The blockade of the anti-CTGF/
integrin αVβ3 pathway might become a new useful strategy for
the treatment of RA.
Materials and methods
Patients and samples
All patients with RA and systemic lupus erythematosus (SLE)
fulfilled the American College of Rheumatology (ACR) criteria
[15]. All patients with Sjögren's syndrome (SS) also fulfilled
the American-European Consensus Criteria (AECC) [16].
Serum samples were obtained from 39 patients with RA, 11
patients with SLE, 4 patients with primary SS and 50 normal
age- and gender-nearly matched healthy volunteers. The syno-
vial tissue samples were obtained from two patients with RA
and osteoarthropathy (OA) as disease controls during a surgi-
cal operation for knee joints arthropathy. The patients with RA
were further categorized as an active RA group (n = 20) and
inactive RA group (n = 19) depending on the elevated serum
C-reactive protein (CRP) level (normal range < 0.3 mg/dl). The
active RA group includes the patients who had received inflix-
imab treatment (n = 10). The precise clinical profiles of these
patients had been described in a previous report and all these
patients had shown disease amelioration by the infliximab
treatment [10]. All patients provided their informed consent to
participate in this study and the study was approved by the
local ethics committee.
Materials and cell lines
A human synovial fibroblasts cell line, MH7A (Riken Cell Bank,
Ibaraki, Japan), isolated from the knee joint of RA, was pro-
vided by Dr. Miyazawa [17]. A human chondrogenic cell line
OUMS-27 was purchased from Health Science ResearchAvailable online http://arthritis-research.com/content/11/6/R174
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Resource Bank (Tokyo, Japan) [18]. MH7A cells and OUMS-
27 cells were cultured in Dulbecco's modified Eagle's medium
(DMEM: Sigma; St. Louis, MO, USA) containing 10% fetal
bovine serum (FBS) under standard conditions. MH7A cells
and OUMS-27 cells were stimulated with or without recom-
binant TNF-α (20 ng/ml in MH7A cells, 50 ng/ml in OUMS-27
cells, respectively) (R&D System; Minneapolis, MN, USA) in
appropriate time (6 and 24 or 48 hours) and used for the sub-
sequent experiments. Treatment with 1 μg/ml of infliximab was
used to inhibit effects of TNF-α in vitro in the experiments.
ELISA for human CTGF
The serum level of CTGF in human sera was evaluated by a
sandwich ELISA system using two different anti-human CTGF
antibodies; monoclonal anti-human CTGF antibody (R&D Sys-
tem, Cat#MAB660) and biotinated anti-human CTGF anti-
body (R&D System, Cat#BAF660). To reduce non-specific
reactions and gain a higher sensitivity, high molecular weight
proteins contained in the sera were removed by Multiple Affin-
ity Removal Spin Cartridge Reagent Kit (Agilent Technologies,
Santa Clara, CA, USA) and used for the serum samples. Mon-
oclonal anti-CTGF antibodies (R&D Systems) were diluted in
phosphate-buffered saline (PBS) to a final concentration of 10
μg/ml and then coated on Optiplate-96F microtiter plates
(PerkinElmer, Waltham, Massachusetts, USA). After a block-
ing step, the serum samples were diluted 1:150 in PBS and
then incubated in the antibody-coated wells at 4°C overnight.
Biotinylated anti-CTGF antibody (R&D systems) was used at
2 μg/ml dilution for the detection and then beta galactosidase
conjugated streptavidin (Rockland Immunochemical for
Research, Gilbertsville, PA, USA) was added. 4-methylumbel-
liferyl-β-D-galactoside (Research Organics, Cleveland, OH,
USA) was used as the detection reagent. Recombinant human
CTGF protein (Biovender Laboratory Medicine Inc, Modrice,
Czech Republic) was used as a standard for the quantitation.
Each sample was analyzed in triplicate and the average optical
density (OD) at 460 nm with an appropriate development time
was used for the data analysis.
Total RNA extraction and real-time RT-PCR
Total RNA was extracted from the MH7A cells, OUMS-27
cells and osteclasts using the Rneasy Mini Kit (QIAGEN,
Hilden, Germany) according to the manufacturer's instruc-
tions. Strands of cDNA were synthesized using a PrimeScript
RT reagent kit (Takara, Shiga, Japan) with 0.5 μg total RNA.
Real-time RT-PCR using SYBR Premix Ex Taq Perfect real
time (Takara) was used for the quantitation of CTGF mRNA.
The primers for human CTGF [GenBank:NP_001892] were
designated as 5' CTTGCGAAGCTGACCTGGAA-3' (for-
ward) and 5'-AGCTCAAACTTGATAGGCTTGGAGA-3'
(reverse), β-actin primers for control primers as 5'-TGGCAC-
CCAGCACAATGAA-3' (forward) and 5'-CTAAGTCAT-
AGTCCGCCTAGAAGCA-3' (reverse), Cathepsin-K primers
as 5'-AGCTGCAATAGCATAATCTGAACC (forward) and 3-
CGTTGTTCTTATTTCGAGCCATGA (reverse) and matrix
metalloproteinase (MMP)-9 primers as 5-ACCTCGAACTTT-
GACAGCGACA (forward) and 3-GATGCCAT-
TCACGTCGTCCTTA (reverse). Quantitative real-time RT-
PCR was performed in 20 μl volume with 500 ng cDNA in
SYBR Premix Ex Taq Kit (Takara). The amplification cycles
consisted of 95°C for five seconds as first steps (one cycle),
95°C for five seconds and 60°C for 30 seconds for CTGF as
second steps (45 cycles), 95°C for five seconds and 60°C for
30 seconds and 95°C for 15 seconds as third steps (one
cycle) according to protocol described in the manufacturer's
instructions (Takara). To determine the quantitative expression
levels of the transcripts, samples loading was monitored and
normalized by the expression of β-actin transcripts.
Osteoclasts differentiation
Peripheral blood monocytes (PBMC) from healthy donors
were collected using Ficoll-gradient centrifugation (Ficoll-
Paque PLUS, GE Healthcare, Chalfont St Giles UK). The
PBMC were purified into a CD14+ population using anti-
CD14 MACS microbeads (Miletenyi Biotec, Auburn, CA,
USA) according to the protocol supplied by the manufacturer.
A flow cytometory analysis using phycoerythrin (PE)-conju-
gated mouse anti-CD14 mAb (Miletenyi Biotec) showed that
purity of the CD14+ monocytes was more than 98% in each
experiment. The purified CD14+ monocytes (5 × 104 cells/
well) were cultured in 96 wells in alpha minimum essential
medium (αMEM, Invitrogen, Grand Island, NY, USA) with 10%
FBS and incubated with M-CSF (25 ng/ml) and soluble
RANKL (sRANKL; 40 ng/ml) (Millipore, Billerica, MA, USA)
with or without bioactive recombinant CTGF (1 μg/ml) (Biov-
ender Laboratory Medicine Inc, Brno, Czech Republic). The
medium was replaced with fresh medium three days later and
the cells were stained for tartrate-resistant acid phosphatase
(TRAP) expression using a commercial kit (Cell Garage,
Tokyo, Japan) after incubation for seven days. The number of
TRAP positive multinucleated cells (MNC) in three randomly
selected fields examined at 100× magnification of the total
number of TRAP-positive MNC per well were counted as oste-
oclasts under light microscopy. For immunoblotting and immu-
noprecipitation analysis, osteoclasts were initially
differentiated by M-CSF (25 ng/ml) and sRANKL (40 ng/ml)
without CTGF for seven days. Then, recombinant CTGF (10
or 50 ng/ml) was added into the cultures and incubated at 5,
15, 60, and 120 minutes in the presence or absence of anti-
CTGF antibody (1 μg/ml). The cells were washed and col-
lected for making cell extracts for subsequent immunoblotting
and immunoprecipitation assays.
Immunoblotting and immunoprecipitation
MH7A and OUMS-27 cells were centrifuged at 200 × g for 30
min. Cell pellets (1 × 107 cells/well) were then resuspended
directly in lysis buffer containing 150 mM NaCl, 1 mM
MgCl2·6H2O, 80 mM Tris-HCl, 0.1% NP-40 and Complete
Protease Inhibitor cocktail (Roche, Mannheim, Germany). The
protein concentrations in the lysates were determined usingArthritis Research & Therapy    Vol 11 No 6    Nozawa et al.
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the Protein DC Assay Kit (Bio-Rad, Hercules, CA, USA) to
ensure equal loading of proteins in each SDS-PAGE lane.
After determining the protein concentration, lysates were
mixed with an equal volume of 2 × gel sample buffer contain-
ing 6% sodium dodecyl sulfate, 20% glycerol, 10% β-mercap-
toethanol, 0.02% bromophenol blue and Complete Protease
Inhibitor cocktail. Lysates were stored at -80°C until use. The
equivalent of 10 μg total lysate protein was loaded onto each
lane of 12.5% SDS-PAGE gels, separated by electrophoresis
and then transferred to nitrocellulose membranes using a
Semi-Dry Trans-Blot apparatus (Bio-Rad). After blocking,
immunoblotting was performed using polyclonal goat anti-
human CTGF (L-20) antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 1:2,000 and monoclonal mouse anti-
human β actin antibody (Sigma) at 1:500 dilution. The detec-
tion of bound antibodies was achieved using horseradish per-
oxidase-conjugated anti-goat IgG antibody and anti-mouse
IgG antibody (Dako, Glostrup, Denmark) used at 1:5,000 and
1:2,500 dilution respectively, in combination with enhanced
chemiluminescence (Super Signal West Pico, PIERCE Prod-
ucts, Rockford, IL, USA). Cell extracts of the osteoclasts stim-
ulated with or without recombinant CTGF were prepared with
the same condition for subsequent immunoblotting and immu-
noprecipitation assays. For immunoprecipitation, 5 μg of
mouse anti-human integrin αVβ3 antibody (Chemicon Interna-
tional, Temecula, CA, USA) were incubated at 4°C overnight
with protein G-conjugated agarose beads. Samples were
washed and resuspended in 2 × gel sample buffer and boiled
prior to immunoblotting. The immunoprecipitation samples or
the cell extract were further subjected to SDS-PAGE and elec-
tro-transferred to the membranes. After blocking, primary anti-
bodies; mouse anti-human integrin αVβ3 antibody (Chemicon
International) at 1:2,000 dilution, mouse anti-human ERK1/
ERK2 antibody (Abcam, Cambridge, MA, USA) at 1:2,000
dilution, and mouse anti-human phospholilated ERK1/ERK2
antibody (Abcam) at 1:10,000 dilution were applied for the
blots at 37°C, 120 minutes. For immunoblotting assay, osteo-
clasts were stimulated with recombinant CTGF (10 and 50
ng/ml) at 60 minutes, then, the extracts were subjected to
SDS-PAGE and electro-transferred to the membranes. The
primary antibodies; mouse anti-human β actin antibody
(Sigma) at 1:500 dilution, rabbit anti-human focal adhesion
kinase (FAK) antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at 1:200 dilution, rabbit anti-human phospho-
lilated FAK at 1:200 dilution were incubated with the blots at
37°C, 120 minutes. The detection of bound antibodies was
achieved using horseradish peroxidase-conjugated anti-goat
IgG antibody, anti-mouse IgG antibody, and anti-rabbit IgG
antibodies (Dako, Denmark) used at 1:5,000 dilution.
Immunohistochemistry analysis
A histochemical analysis with indirect immunofluorescence
microscopy was performed. Briefly, serial paraffin sections
derived from surgical samples were deparaffinized, rehydrated
and washed with PBS as previously reported [19]. Double
staining for CTGF and F4/80, which is widely used as a spe-
cific marker for macrophage, was performed. The samples
were incubated with 10% bovine serum albumin (Sigma) for
60 minutes to eliminate nonspecific binding, and then incu-
bated with goat anti-human CTGF (L-20) antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and rat anti-human
F4/80 antibody (Abcam) for 60 minutes diluted 1:50 in PBS.
After washing, the bound antibodies were labeled with
Alexa468 (Invitrogen Corporation, Carlsbad, CA, USA) conju-
gated anti-goat IgG antibody (Invitrogen Corporation,
Carlsbad, CA, USA) and Alexa594 conjugated anti-rat IgG
antibody (Molecular Probe) for detection of fluorescence
images. The sections were counterstained by the nuclear stain
40,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories,
Burlingame, CA, USA). The other sections were also stained
with hematoxylin/eosin (HE).
Resorption assay
Purified CD14+ monocytes were seeded onto plates coated
with calcium phosphate thin films (Biocoat Osteologic, BD
Biosciences, San Jose, CA, USA) and were incubated with
sRANKL (40 ng/ml) + M-CSF (25 ng/ml) in combination with
or without CTGF (1 μg/ml) for seven days. The cells were then
lysed in bleach solution (6% NaOCl, 5.2% NaCl). The resorp-
tion lacunae were examined under light microscopy.
Statistical analysis
The experimental data were compared using un-pared Stu-
dent's t-test with P values < 0.05 considered to be statistically
significant.
Results
Increased serum levels of CTGF in patients with RA
Figure 1A shows the serum levels of CTGF in the patients with
RA, disease controls (SLE and SS) and normal controls. The
serum levels of CTGF in RA patients were significantly greater
in comparison to normal controls or disease controls (P <
0.05). There were no significant differences in the serum
CTGF concentrations between disease controls and normal
controls. When cut off value (dotted line) was defined as the
mean value of normal controls + three standard deviations
[20], 25.8% of RA patients (eight in 39 patients) showed ele-
vation of serum CTGF level. In contrast, none of the disease
and normal controls showed any elevation of CTGF levels in
their sera.
Correlation between CTGF and diseases activity
Serum CTGF levels were compared between the patients hav-
ing high and low RA disease activities (Figure 1B) and the
effect of infliximab on the serum levels of CTGF was examined
in RA patients (Figure 1C). We could not fully obtain informa-
tion of articular manifestations with these patients, therefore,
the patients were provisionally divided into two groups, active/
inactive RA, depending upon the serum level of CRP (active
RA; CRP > 0.3 mg/ml, inactive RA; CRP < 0.3 mg/ml). OtherAvailable online http://arthritis-research.com/content/11/6/R174
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comparative parameters such as erythrocyte sedimentation
rate (ESR), white blood cell (WBC), and matrix metallopro-
tease-3 (MMP-3) were also significantly elevated in the active
RA group (Table 1). As shown in Figure 1B, the levels of serum
CTGF were significantly elevated in active RA compared with
inactive RA. Interestingly, the frequency of sera with elevated
CTGF levels designed as above the cut off points was signifi-
cantly greater in the active RA group than the inactive RA
group (7/20 vs 1/19, P < 0.05) (Table 1). Figure 1C shows a
reduction of serum CTGF levels in response to infliximab treat-
ment. The statistical reduction of serum CTGF levels was
observed after infliximab treatement (P < 0.05) (Figure 1C).
These data suggest that serum levels of CTGF correlate with
the disease activity and concern a pathogenesis of RA.
Effects of TNF-α for the production of CTGF from 
synovial fibroblasts or chondrocytes
To investigate the CTGF contribution for pathogenesis of RA,
the CTGF expression was evaluated by immunohistochemical
analysis in synovial tissues of surgical samples from the knee
joint of RA patients and OA patients as a disease control. An
inflamed synovial tissue was recognized in samples from RA
compared to OA in HE staining (Figure 2A). A strong expres-
sion of CTGF was observed in inflamed synovial tissue with
RA, and none or very weak expression was recognized in sam-
ples with OA (Figure 2B). Inflamed synovial tissue of RA gen-
erally consists of fibroblasts and lineage of hemapoietic cells
such as macrophage, neutrophils, and lymphocytes. To inves-
tigate a more specific production site of CTGF, the samples
were also stained by anti-F4/80 antibody, which is generally
used for a specific marker of macrophages. As expected, a
significant infiltration of macrophages was observed in RA
compared to OA (Figure 2C). Double staining using anti-
CTGF antibody and anti-F4/80 antibody showed that expres-
sion of CTGF and F4/80 was not overlapped (Figure 2D), sug-
gesting that these molecules were produced at different sites.
Because it has been reported that CTGF was not generally
expressed in hemopoietic lineage cells [14], we considered
Figure 1
The serum levels of connective tissue growth factor in patients with rheumatoid arthritis The serum levels of connective tissue growth factor in patients with rheumatoid arthritis. The serum concentration of connective tissue growth factor 
(CTGF) in patients with RA (n = 39), SLE and SS (n = 15) and normal healthy controls (n = 50) were measured using a sandwich ELISA (Figure 
1A). Dotted line (Figure 1A) indicates the cut off point designed as the mean OD + 3 SD for normal sera. Value above the cut off point was defined 
as an elevated serum CTGF concentration. Comparison of the serum concentrations of CTGF between active (n = 20) and inactive (n = 19) RA 
patient was shown (Figure 1B). Comparison of the serum concentrations of CTGF between before and after Infliximab treatment was also shown 
(Figure 1C). The sera treated with infliximab (n = 10) were collected at post 24 hrs after the first administration. Bars in 1B and 1C indicate the SD.
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Table 1
Patient profile with active/inactive rheumatoid arthritis
Active RA
(n = 20)
Inactive RA
(n = 19)
P value
CRP (mg/ml) 3.38 ± 2.83 < 0.3 P < 0.01
ESR (mm/h) 69.9 ± 29.7 19.5 ± 13.2 P < 0.05
WBC (cells/ml3) 8235 ± 3200 5470 ± 552 P < 0.05
MMP-3 (ng/ml) 402.0 ± 307.9 103.1 ± 73.3 P < 0.05
Frequency of CTGF elevated sera 35.0% (7/20) 5.3% (1/19) P < 0.05
CTGF = connective tissue growth factor; RA = rheumatoid arthritis; CRP = C reactive protein; ESR = erythrocyte sedimentation rate; WBC = 
white blood cell; MMP = matrix metalloproteinase.Arthritis Research & Therapy    Vol 11 No 6    Nozawa et al.
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Figure 2
Connective tissue growth factor expression in synovial tissue of patients with rheumatoid arthritis Connective tissue growth factor expression in synovial tissue of patients with rheumatoid arthritis. The representative results of HE staining (Figure 
2A), immunofluorescence anti-CTGF antibody staining (Figure 2B; green), and anti-F4/80 antibody staining (Figure 2C; red) are shown using surgi-
cal samples from RA and OA patients. The samples were counterstained by DAPI (blue) for nuclear staining and merge images are shown (Figure 
2D). A strong expression of CTGF and F4/80 was observed in the samples of RA compared to OA and the CTGF expression cells were not over-
lapped with F/40 expression cells indicating that CTGF is upregulated in synovial fibroblasts rather than macrophages.
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that CTGF was mainly produced at synovial fibroblasts in
inflamed synovial tissues with RA rather than hemopoietic cells
like macrophages.
In order to investigate how TNF-α regulates the production of
CTGF in synovial fibroblasts, CTGF expression was measured
in MH7A cells (human synovial fibroblasts cell line) stimulated
with or without recombinant TNF-α. Furthermore, as it is well
known that cartilage tissue, which is also a typical site dam-
aged by RA, is affected by TNF-α, a similar experiment was
performed using OUMS-27 cells (human condrocytes cell
line). The results obtained by immunoblotting and quantitative
real time PCR revealed that TNF-α enhanced the expression
of CTGF in MH7A cells and this enhancement was neutralized
by infliximab (Figure 3A). The influence of TNF-α on CTGF pro-
duction for chondrocytes was also investigated using the
OUMS-27. In contrast to synovial fibroblasts, CTGF produc-
tion was oppositely diminished by TNF-α stimulation and this
inhibitory effect was restored by infliximab (Figure 3B). These
data suggest that TNF-α can distinctly regulate CTGF produc-
tion in a cell dependent manner.
Synergistic effects of CTGF on osteoclastgenesis mediated 
with M-CSF/RANKL
Next, the effect of CTGF on osteoclastogenesis was examined
in order to investigate functional roles of CTGF on the RA-
related bone destruction. Although CTGF alone had no capa-
bility for the differentiation of osteoclasts (data not shown), M-
CSF/RANKL-mediated osteoclastogenesis was enhanced by
the presence of CTGF not only in the morphological size but
also in the number of osteoclasts and this enhancing effect
was neutralized by anti-CTGF antibody (Figure 4A and 4B).
Next, the effect of CTGF for the osteoclastic function was also
investigated. Bone resorption mediated by osteoclasts, which
represents vacant areas indicated by arrows in Figure 5A, was
enhanced in the presence of CTGF and this effect was also
neutralized by anti-CTGF antibody (Figure 5A). Furthermore,
the productions of cathepsin-K and MMP-9, which are repre-
sentative osteoclastic specific catalytic enzymes, were also
Figure 3
Effects of TNF-α on the regulation of connective tissue growth factor production in articular cells Effects of TNF-α on the regulation of connective tissue growth factor production in articular cells. CTGF production in the human synovial fibroblasts 
cell line (MH7A) (Figure 3A) in human chondrocytes cell line (OUMS-27) (Figure 3B) stimulated with/without TNF-α were evaluated by immunoblot-
ting and quantitative real time PCR. TNF-α promoted CTGF production in MH7A and oppositely inhibited the production in OUMS-27.
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enhanced by the presence of CTGF with M-CSF/RANKL in
comparison to the absence of CTGF in the culture (Figure 5B).
These data suggest CTGF promote osteoclastogenesis in the
presence of M-CSF/RANKL and excessive CTGF is an impor-
tant factor of aberrant osteoclasts activation in RA
pathogenesis.
CTGF activates focal adhesion kinase (FAK) and 
extracellular signal-regulated kinase (ERK) 1/2 through 
integrin αVβ3 on the osteoclasts
Although a specific receptor of CTGF has not been fully iden-
tified so far, several molecules have been reported as CTGF
receptors. Chen and co-workers reported that a neutralizing
antibody against integrin αVβ3 significantly attenuated CTGF-
mediated ERK1/2 activation and cellular migration in human
breast cancer cells, indicating that the integrin αVβ3-ERK1/2
signaling pathway is crucial in mediating CTGF function [21].
Furthermore, Tan and co-workers very recently found that
CTGF stimulation increased the phosphorylation of FAK and
ERK via integrin αVβ3 resulting in the migration and expres-
sion of matrix metalloproteinase (MMP)-13 in human chondro-
sarcoma cells [22]. To date, several cell lines of evidence have
shown that, among various integrins, osteoclasts express very
high levels of integrin αVβ3 and it is now well accepted that
this integrin is a central molecule for osteoclastic bone resorp-
tion [23]. Therefore we considered that excessive CTGF pro-
duced by synovial fibroblasts in RA contribute to increased
osteoclastic function through integrin αVβ3 signaling as well
as other type of cells. To assess molecular actions of CTGF on
osteoclasts, immunoprecipitation and immunoblotting analysis
were performed. Figure 6 indicated that phosphorylated
ERK1/2 was recruited by integrin αVβ3 upon CTGF stimula-
tion (Figure 6A), and CTGF also induced FAK phosporylation
(Figure 6B). These data suggest that integrin αVβ3 is a recep-
Figure 4
Synergistic effects of connective tissue growth factor for M-CSF/sRANKL-mediated osteoclastogenesis Synergistic effects of connective tissue growth factor for M-CSF/sRANKL-mediated osteoclastogenesis. Figure 4A shows pictures of TRAP staining 
and Figure 4B shows the numbers of TRAP positive cells. The TRAP positive cells stained by red were indicated by arrows. CTGF increased not 
only number but also morphological size of differentiated osteoclasts in combination with M-CSF/RANKL. Bars in Figure 4B indicate the SD.
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tor of CTGF and CTGF could enhance osteoclastic function
through activation of integrin αVβ3 signaling transduction
pathways such as ERK1/2 and FAK phosphorylation.
Discussion
This study was conducted to investigate roles of CTGF for the
possible pathogenesis of RA. We found novel findings as fol-
lows: I) serum levels of CTGF in RA were significantly greater
than those of disease controls (SLE and SS) and normal
healthy controls (Figure 1A); II) serum concentrations of
CTGF were significantly elevated in patients with active RA
compared to inactive RA (Figure 1B), furthermore, a significant
reduction of the serum CTGF level was observed by infliximab
administration concomitant with the disease amelioration (Fig-
ure 1C); III) immunohistochemical studies reveal that CTGF
appears to be massively produced by synovial fibloblasts in
RA (Figure 2); IV) the production of CTGF in synovial fibrob-
lasts was up-regulated by TNF-α stimulation (Figure 3A) and
those of CTGF in chondrocytes were oppositely down-regu-
lated (Figure 3B); V) CTGF possessed a synergistic effect in
combination with MCSF/RANKL for osteoclastogenesis
through integrin αVβ3 signaling on the osteoclasts (Figures 4,
5 and 6). Taken together, a schematic hypothesis of the role
of CTGF in the RA pathogenesis is presented in Figure 7. It
has been reported that CTGF adenovirus vector transfection
into knee joints of mice induces linier overexpression of CTGF
in the synovium and results in cartilage damages with increas-
ing of mRNA cording for degradative enzymes such as MMP-
3 [24]. Manns and co-workers also reported that CTGF is up-
regulated in an experimental animal model of RA, and they
have shown that treatment with thrombospondin (TSP)-1-
derived peptide is associated with down-regulation of CTGF
Figure 5
Synergistic effects of connective tissue growth factor on M-CSF/sRANKL-mediated osteoclastic function Synergistic effects of connective tissue growth factor on M-CSF/sRANKL-mediated osteoclastic function. Figure 5A shows the results of the resorp-
tion of osteoclasts on calcium phosphate. Vacant regions indicated by arrows represent the areas where the osteoclasts actually absorbed. There 
was no vacant region in negative control cells (M-CSF alone). In contrast to negative control, significant vacant regions were observed in osteoclasts 
induced by M-CSF/sRANKL. CTGF further expanded the vacant areas in combination with M-CSF/sRANKL and anti-CTGF antibody neutralized this 
effect. Figure 5B shows the levels of expression of osteoclasts specific proteases (MMP-9 and cathepsin-K) measured by quantitative real time RT-
PCR. Synergistic effect of CTGF was also observed for M-CSF/sRANKL-mediated osteoclastogenesis. Bars in Figure 5B indicate the SD.
B
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concomitant with the disease amelioration [25]. Furthermore,
the null knock-down of the CTGF gene dramatically inhibits
osteoclast-like formation in mice [26]. Their reports indicate
that CTGF has a significant role for RA pathogenesis and our
present data can support these previous reports.
The synovial tissue in the inflamed joints of RA can invade
bones and this is supported by the invasive nature of the syn-
ovial fibroblasts gaining the capacity to move and penetrate
into cartilages and bones. Osteoclasts are the sole bone-
absorbing cells and the functions of osteoclasts are increased
in RA patients as well as in patients with osteoporosis. Osteo-
clasts are commonly found within the erosive pit at the interfer-
ence of synovial inflammatory tissue and subchondral bone
[27]. RANKL is a membrane-residing protein on osteoblasts
and recognizes its receptor (RANK) expressed on marrow
macrophages, promoting them to differentiate into the osteo-
clast phenotype in the presence of M-CSF [28-30]. These
molecules are expressed locally in the synovial tissues of RA
patients and TNF-α is an inducer of RANKL expression as well
as IL-1 and IL-6 [31,32]. Therefore, aberrant osteoclastogen-
esis play an important role in the development of RA and this
process is further positively regulated by proinflammatory
cytokines like TNF-α under pathogenic conditions. As shown
in Figure 2, strong CTGF expression appeared to be observed
at inflamed synovial fibroblasts derived from surgical samples
of RA patients. Furthermore, CTGF was upregulated by TNF-
α in human synovial fibroblasts cell line, MH7A, as shown in
Figure 3A. The present data indicate that excessive CTGF pro-
duction from synovial fibroblasts with RA patients induced by
TNF-α can promote aberrant activation of osteoclasts in com-
bination with RANKL/M-CSF, resulting in bone destruction.
In addition, we found a CTGF receptor, integrin αVβ3, on the
osteoclasts. Integrins are heterodimec adhesion receptors
that mediate cell-matrix interaction. Osteoclasts exhibit high
expression of the integrin αVβ3, which binds to a variety of
extracellular matrix proteins including vitronectin, osteopontin,
and bone sialoprotein. Arg-Gly-Asp (RGD)-containing pep-
tides, RGD-mimitics, and blocking antibodies to integrin αVβ3
were shown to inhibit bone resorption in vitro and in vivo, sug-
gesting that this integrin may play an important role in osteo-
clast function [23]. It has been shown that CTGF could
interact with integrin αVβ3 in other types of cells, however, it
has not been shown to our knowledge that integrin αVβ3 on
the osteoclasts interact with CTGF. Furthermore, blocking of
the integrin αVβ3 signaling pathway has been shown to
increase bone mineral density in women with postmenoposal
osteoporosis [20]. CTGF/Integrin αVβ3 pathway is now
receiving considerable attention as a therapeutic target in dis-
eases associated with increased bone resorption, such as RA.
Therefore, we insist that our findings are very important for the
understanding of CTGF/integrin αVβ3 contribution to disease
progression in RA.
Figure 6
Connective tissue growth factor mediate ERK1/2 and focal adhesion  kinase activation through integrin αVβ3 signal transduction Connective tissue growth factor mediate ERK1/2 and focal adhesion 
kinase activation through integrin αVβ3 signal transduction. Figure 6A 
shows the immnoprecipitation and immunoblotting analysis. The cell 
extracts of osteoclasts stimulated with recombinant CTGF (10 or 50 
ng/ml) at 60 minutes were precipitated using anti-integrin αVβ3 anti-
body and subsequently blotted with anti- phosphorylated ERK1/ERK2, 
conventional ERK1/ERK2, and integrin αVβ3 antibodies respectively. 
The phosphorylated ERK1/ERK2 was recruited with integrin αVβ3 by 
CTGF stimulation. Figure 6B shows the immunoblotting analysis using 
anti- phosphorylated FAK, conventional FAK, and β-actin antibodies in 
the osteoclasts extracts treated with CTGF (10 ng/ml) at 5, 15, 60, and 
120 minutes in the presence or absence of anti-CTGF antibody (1 μg/
ml). CTGF stimulation resulted in phosphorylation of FAK from 60 min-
utes and this effect was neutralized by anti-CTGF antibody suggesting 
activation of signal transduction pathways through integrin αVβ3.
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Recently anti-TNF-α blocking reagents are becoming more
widely available in practical treatments for RA patients [33].
Significant beneficial effects of infliximab on bone destruction
have been reported even in RA patients without improvements
of RA-related clinical symptoms [34]. Therefore, other mecha-
nisms besides the blocking of inflammatory reactions like CRP
or ESR elevation appear to be associated with infliximab-medi-
ated inhibition of articular damage in RA patients. The inhibi-
tion of CTGF production from synovial cells mediated by
infliximab may play an important role in the blocking of bone
destruction in RA patients. In this study, we also measured
serum levels of TNF-α concomitant with CTGF, however, sig-
nificant correlation with serum levels of TNF-α and CTGF was
not observed (data not shown). These data suggest that high
levels of serum CTGF in active RA patients are not merely
mediated by the production from synovial fibroblasts with TNF-
α stimulation. Furthermore, although the production of CTGF
has been reported to be induced by TGF-α in connective tis-
sues [14], no specific correlation was also observed between
CTGF and TGF-α concentrations in the sera of RA patients
(data not shown). One possible explanation for these dissoci-
ations, high levels of serum CTGF production in active RA is
mediated by other multiple stimulating factors or productive
sites. In fact, IL-6, which is also the main proinflamatory
cytokine related to RA pathogenesis, was reported as the
stimulating factor of CTGF production [35]. Furthermore, vas-
cular endothelial cells, which are also affected by RA, are
known as major productive sites of CTGF [14]. These factors
might be involved in mechanisms of the elevation of serum
CTGF in active RA.
In our study, TNF-α can induce CTGF production from syno-
vial cells. In contrast, TNF-α could oppositely inhibit the pro-
duction of CTGF from chondrocytes. It has been proposed
that CTGF contributes to maintaining cartilage homeostasis
by the autocrine system [14]. CTGF also might promote the
direct proliferation of osteoblasts [14]. Therefore, CTGF may
possess positive regulatory functions for chondrocytes and
osteoblasts to keep physiological articular homeostasis.
Therefore, reduction of CTGF from condrocytes may result in
cartilage damage. These dual mechanisms of CTGF appear to
be important for the pathogenesis of RA. It was reported that
treatment with TNF-α significantly increased CTGF on cul-
tured mesangial cells and pancreatic stellate cells [36,37]. On
the contrary, Yu and co-workers recently reported that TNF-α
suppressed TGF-α mediated CTGF production by alteration
of TGF-α signal transduction [38]. Although the precise mech-
anism for why CTGF production can be distinctively regulated
by TNF-α has not been elucidated to date, one possible expla-
nation is that TNF-α has multiple biological functions depend-
Figure 7
Hypothesis of the role of connective tissue growth factor in the possible rheumatoid arthritis pathogenesis Hypothesis of the role of connective tissue growth factor in the possible rheumatoid arthritis pathogenesis.
Excessive TNF-D production in RA
Synovial fibroblasts 
CTGF
Condrocytes
CTGF
(autocrine)
Articular destruction (damage of bone and cartilage)
Precursor cells Osteoclasts
Differentiation 
to osteoclasts
Increased 
bone resorption
Condrocytes
Impaired regeneration 
of cartilage
integrin DVE3 unknown ligand unknown ligandArthritis Research & Therapy    Vol 11 No 6    Nozawa et al.
Page 12 of 13
(page number not for citation purposes)
ing upon cell types, and multiple receptors (TNF-receptor 1
and TNF-receptor 2) are responsible for the appearance of the
functions. Wehling and co-workers recently reported that IL-
1β and TNF-α inhibited chondrogenesis from mesenchymal
stem cells into chondrocytes in a dose-dependent manner and
this was associated with a marked activation of NF-κB [39],
also Polzer and co-workers reported that although wild-type
mice showed no signs of cartilage damage, human TNF trans-
genic mice exhibited progressive proteoglycan loss starting at
the clinical onset of arthritis [40]. These data suggest
chondrocytes and cartilage tissue were given destructive
effects by TNF-α. Otherwise, Mun and co-workers reported
that TNF-α-induced interleukin-32, which is a recently discov-
ered proinflamatory cytokine that appears to play a critical role
in human rheumatoid arthritis (RA), is positively regulated via
the Syk/protein kinase Cδ/JNK pathway in rheumatoid synovial
fibroblasts [41]. Gao also reported that the proinflammatory
cytokines IL-1β and TNF-α induce the expression of Synovio-
lin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the
Erk1/2-ETS1 pathway indicating that the proinflammatory
cytokines IL-1β and TNF-α induce the overgrowth of synovial
cells by upregulating Synoviolin expression via the Erk1/-ETS1
pathway [42]. Their reports indicate that TNF-α appears to
possess proinflamatory or proliferative effects against synovial
fibroblasts resulting in further diseases progression of RA. In
the diseases condition with RA, TNF-α mediates various bio-
logical effects depend on the cell types in order to progress or
maintain the disease effectively. This may be an important
mechanism of efficacy in TNF-α blocking therapy, which can
suppress multiple functions of TNF-α, for the inhibition of bone
destruction and/or promotion of cartilage regeneration in
patients with RA.
Our previous report of mass spectrometric analysis of low
molecular weight serum proteins of RA patients shows that
CTGF was more frequently detected in the low molecular
weight fraction after infliximab treatment of RA patients [10].
The precise reasons for this discrepancy are still unclear.
However, the apparent molecular mass of the serum CTGF
molecule or molecular complex(es) in RA patients may be out
of the range of the ultrafiltration pre-fractionation used in pre-
vious protein analysis. Furthermore, the molecular size of the
recovered proteins may be changed by partial proteolysis or
dissociation of protein complex(es) of CTGF after infliximab
treatment.
Taken together, our study indicated an important role of CTGF
in the development of bone destruction in patients with RA
and suggested a mechanism explaining the efficacy of anti-
TNF-α antibodies in the prevention of bone destruction in RA.
The present data suggest that CTGF plays significant roles in
the pathogenesis of RA especially through aberrant activation
of osteoclasts and disturbance of cartilage tissue homeosta-
sis, thus resulting in articular destruction. In addition, it is pos-
sible that the blockade of the CTGF/integrin αVβ3 signaling
pathway by neutralizing antibody has beneficial effects in the
treatment of RA. The administration of anti-CTGF antibodies
to RA model mice in vivo will be conducted in the future.
These results may open new therapeutic strategies for
patients with RA and the possibility of development of more
specific biological therapies rather than antibodies to TNF-α.
Conclusions
This study was conducted to investigate roles of CTGF in the
possible pathogenesis of RA. Our data indicate that excessive
CTGF induced by TNF-α can promote aberrant activation of
osteoclasts in combination with RANKL/M-CSF, resulting in
bone destruction. In contrast, TNF-α could oppositely inhibit
the production of CTGF from chondrocytes. It has been pro-
posed that CTGF contributes to maintaining cartilage home-
ostasis by the autocrine system. Therefore, reduction of CTGF
from condrocytes may result in cartilage damage. These dual
mechanisms of CTGF appear to be important in the pathogen-
esis of RA. This may be an important mechanism of efficacy in
TNF-α blocking reagents therapy on the inhibition of bone
destruction and/or promotion of cartilage regeneration in
patients with RA.
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